Relmada Therapeutics Inc

NASDAQ RLMD

Data sourced from

and

Daily

Download Data

Relmada Therapeutics Inc Market Capitalization on June 03, 2024: USD 92.94 M

Relmada Therapeutics Inc Market Capitalization is USD 92.94 M on June 03, 2024, a 8.34% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Relmada Therapeutics Inc 52-week high Market Capitalization is USD 208.60 M on March 01, 2024, which is 124.46% above the current Market Capitalization.
Relmada Therapeutics Inc 52-week low Market Capitalization is USD 72.84 M on June 27, 2023, which is -21.62% below the current Market Capitalization.
Relmada Therapeutics Inc average Market Capitalization for the last 52 weeks is USD 106.50 M.

NASDAQ: RLMD

Relmada Therapeutics Inc

CEO	Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD
IPO Date	Oct. 9, 2014
Location	United States
Headquarters	2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134
Employees	20
Sector	Healthcare
Industry	Biotechnology

Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Key trends